Core Insights - Generac Holdings Inc. has been named a finalist in the Mega Category for the 37th Annual Wisconsin Manufacturer of the Year Awards, highlighting its commitment to manufacturing, innovation, and community impact in Wisconsin [1] Company Achievements - Generac has been operating in Wisconsin for over 65 years and currently employs more than 4,800 people across ten locations, including six manufacturing facilities [1] - In 2025, Generac donated approximately $1 million through its Generac Gives program to support education, disaster relief, and community vitality [1] - The company received the Founding Partner Legacy Award for 25 years of partnership with GPS Education Partners, contributing to the development of new manufacturing professionals [1] Product and Facility Developments - Generac launched a new product line in Oshkosh to meet the increasing demand for backup power in data centers [1] - The company opened a new 345,000 square-foot manufacturing facility in Beaver Dam, Wisconsin, creating hundreds of new jobs and representing a significant investment in the local economy [1] - Generac's Energy Technology division introduced PWRmicro, a microinverter designed to enhance energy capture from solar panels [1] - The Commercial & Industrial business unveiled a new line of generators tailored for high-capacity applications in data centers, driven by the growth of Artificial Intelligence [1] - A significant upgrade to the residential product line was introduced, providing homeowners with enhanced control over energy needs amid rising grid instability and energy costs [1]

Core Insights - Cogent Communications reported a service revenue of $975.8 million for the full year 2025, a decrease from $1,036 million in 2024, with a notable increase in wavelength revenue by 100.3% to $38.5 million for the same period [1] - The company experienced a decrease in total customer connections by 4.7% year-over-year, totaling 117,643 as of December 31, 2025 [1] - EBITDA, as adjusted, for Q4 2025 was $76.7 million, reflecting a 4.0% increase from Q3 2025 and a 14.8% increase from Q4 2024 [1] Financial Performance - Service revenue for Q4 2025 was $240.5 million, down 0.6% from Q3 2025 and down 4.7% from Q4 2024 [1] - On-net revenue for Q4 2025 was $134.3 million, a decrease of 0.7% from Q3 2025 but an increase of 4.3% from Q4 2024 [1] - Off-net revenue for Q4 2025 was $92.9 million, down 2.3% from Q3 2025 and down 17.9% from Q4 2024 [1] Customer Connections - On-net customer connections increased by 0.5% year-over-year to 87,944 as of December 31, 2025, while off-net connections decreased by 14.9% to 24,656 [1] - Wavelength customer connections rose by 84.6% year-over-year to 2,064 as of December 31, 2025 [1] - Non-core customer connections decreased to 2,979 as of December 31, 2025, down from 5,802 a year earlier [1] Dividends and Tax Treatment - Cogent paid a total of $150.1 million in dividends for 2025, equating to $3.05 per share, with 100% treated as a return of capital for tax purposes [1] - A regular quarterly dividend of $0.02 per share was approved on February 18, 2026, payable on March 20, 2026 [1] Operational Highlights - The company has expanded its optical wavelength services to 1,068 locations across the U.S., Mexico, and Canada as of December 31, 2025 [1] - The acquisition of the Sprint network has allowed Cogent to enhance its product offerings significantly [1]

KLAR DEADLINE ALERT: Hagens Berman Notifies Klarna Group plc (KLAR) Investors of Today's Lead Plaintiff Deadline in IPO Securities Class Action [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors in Klarna Group plc (NYSE: KLAR) of the upcoming February 20, 2026, lead plaintiff deadline in a pending securities class action. The firm is actively investigating the lawsuit's claims of alleged misstatemen ...

Core Viewpoint - Brainstorm Cell Therapeutics has secured a strategic private placement of $1 million, reflecting confidence in its operational momentum and the value of its NurOwn® platform [1] Financing Details - The financing is structured in two tranches, with the first payment of $500,000 already received and the second payment of $500,000 expected within 30 days [1] - The common stock was priced at $0.60 per share, a significant premium to the $0.54 closing price on February 9, 2026 [1] - The investment includes 120% warrant coverage for five years with an exercise price of $1.00 per share, indicating a nearly 100% premium to the recent market close [1] Company Strategy and Future Plans - The financing follows a period of strategic activity, including finalizing the Phase 3b trial design under a Special Protocol Assessment (SPA) and discussions regarding a Citizens Petition for Accelerated Approval [1] - Proceeds from the financing will support ongoing regulatory initiatives, prepayments for the upcoming Phase 3b trial of NurOwn® in ALS, and general corporate purposes [1] About NurOwn® Technology - NurOwn® technology involves autologous MSC-NTF cells, which are designed to deliver neurotrophic factors and immunomodulatory cytokines to target neurodegenerative diseases [1] - The platform has received Orphan Drug designation from both the FDA and the EMA, with a Phase 3 trial in ALS completed and a second Phase 3b trial set to launch [1] Company Background - Brainstorm Cell Therapeutics is focused on developing autologous adult stem cell therapies for neurodegenerative diseases, with a proprietary platform aimed at modulating neuroinflammation and promoting neuroprotection [1]

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. for alleged violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a) and Rule 10b-5 [1] Summary by Relevant Sections - The lawsuit is focused on shareholders who purchased shares of PayPal during the specified class period [1] - Investors are encouraged to contact the DJS Law Group for potential lead plaintiff appointments [1]

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its CELLECTRA device and its impact on FDA filing timelines [1] Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from October 10, 2023, to December 26, 2025, with a deadline for participation set for April 7, 2026 [1] - Allegations include that Inovio's public statements were materially misleading due to manufacturing deficiencies that could delay the filing of a Biologics License Application (BLA) with the FDA [1] Group 2: Company Impact - The lawsuit claims that Inovio did not gather necessary evidence to support a priority review by the FDA, further compounding the misleading nature of its public statements [1] - Shareholders who purchased shares during the class period and suffered losses are encouraged to contact the DJS Law Group for potential recovery [1]

Core Viewpoint - Masonite International Corporation is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its share repurchase activities while in possession of acquisition offers from Owens Corning at higher prices [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from June 5, 2023, to February 8, 2024, with a deadline for participation set for April 7, 2026 [1]. - The complaint alleges that Masonite repurchased shares from investors while having knowledge of acquisition offers that would have significantly increased share prices [1]. Group 2: Investor Information - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this appointment is not necessary to participate in any recovery [1]. - The DJS Law Group specializes in securities class actions and aims to enhance investor returns through advocacy and counseling [1].

Core Viewpoint - Kyndryl Holdings, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its financial performance and internal controls during the class period from August 7, 2024, to February 9, 2026 [1]. Group 1: Lawsuit Details - The lawsuit alleges that Kyndryl's financial statements were misstated throughout the class period, leading to materially misleading public statements [1]. - The deadline for shareholders to participate in the lawsuit is April 13, 2026 [1]. - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments [1]. Group 2: Company Background - Kyndryl Holdings, Inc. is listed on the NYSE under the ticker symbol KD [1]. - The DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [1].

Core Viewpoint - REGENXBIO Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding the safety and efficacy of its RGX-111 product candidate, which led to a clinical hold by the FDA after a participant developed a tumor [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from February 9, 2022, to January 27, 2026, with a deadline for lead plaintiff appointments set for April 14, 2026 [1]. - The complaint alleges that REGENXBIO consistently made positive statements about RGX-111 while concealing adverse safety and efficacy information from investors [1]. Group 2: Impact on Shareholders - Shareholders who purchased RGNX shares during the class period are encouraged to contact the DJS Law Group regarding potential recovery of losses [1]. - The lawsuit highlights the potential financial impact on shareholders due to the misleading public statements made by the company [1].

Core Insights - The FDA has approved the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia (CLL), marking a significant advancement in treatment options [1][2] Group 1: FDA Approval and Treatment Significance - The approval is based on data from the Phase 3 AMPLIFY trial, establishing this regimen as the first all-oral, fixed-duration treatment for previously untreated CLL patients [1] - This combination offers patients the potential for time off treatment, enhancing long-term disease management [1][3] - The approval expands treatment choices for patients and healthcare providers, facilitating more targeted treatment decisions in CLL [1][3] Group 2: AMPLIFY Study Details - The AMPLIFY trial evaluated VENCLEXTA plus acalabrutinib against chemoimmunotherapy in previously untreated CLL patients without del(17p) or TP53 mutation [1] - Results indicated that the combination regimen reduced the risk of disease progression or death by 35% compared to chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.0038) [1] - Median progression-free survival (PFS) was not reached for the combination regimen, while it was 47.6 months for chemoimmunotherapy [1] Group 3: Safety Profile - The safety profile of the combination regimen aligns with the known safety profiles of each individual therapy [1] - Common adverse reactions (20%) include neutropenia, headache, diarrhea, musculoskeletal pain, and COVID-19 [1] - Serious adverse reactions (2%) include COVID-19 pneumonia (9%), second primary malignancies (2.7%), and neutropenia (2.1%) [1]